Skip to main content

Table 1 Characteristics of AML patients

From: CBFB-MYH11 hypomethylation signature and PBX3 differential methylation revealed by targeted bisulfite sequencing in patients with acute myeloid leukemia

Sample ID Genetic aberration Clinical characterization FAB subtype Gender Material % blasts
AML_1 CBFB-MYH11, FLT3- ITD de novo AML AML M4 male BM 68
AML_2 CBFB-MYH11 de novo AML AML M4 female PB 40
AML_3 NPM1 therapy-related AML* AML M1 female PB 67
AML_4 MLL-PTD therapy-related AML* AML M4 female BM 42
AML_5 NPM1, DNMT3A, FLT3- ITD AML with multilineage dysplasia AML M2 female PB 58
AML_6 none AML with multilineage dysplasia AML M1 female BM 82
AML_7 NPM1, DNMT3A, FLT3- ITD de novo AML AML M4 male BM 94
AML_8 FLT3- ITD de novo AML AML M1 male BM 87
AML_9 FLT3- ITD de novo AML AML M1 male BM 89
AML_10 NPM1, FLT3- ITD de novo AML AML M2 female BM 75
AML_11 MLL-PTD de novo AML AML M1 male BM 92
AML_12 MLL-PTD, CEBPA de novo AML AML M1 female PB 80
AML_13 NPM1, CEBPA AML after MDS AML M6 male PB 60
AML_14 none AML after MDS AML M2 male PB 44
CD34+   pool of 4 CD34+ healthy control cells   males   
  1. AML_1 to AML_14 are AML patients at diagnosis that were subjected to targeted bisulfite sequencing and gene expression profiling; CD34+ is a healthy control's pool; *after breast cancer; BM - bone marrow, PB - peripheral blood.